BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 31476529)

  • 21. Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non-small-cell lung cancer in China.
    Jiang Y; Wang X
    Eur J Hosp Pharm; 2022 May; 29(3):139-144. PubMed ID: 32737070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
    Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Vandormael K; Riccio A; Yang J; Pietanza MC; Brahmer JR
    J Clin Oncol; 2019 Mar; 37(7):537-546. PubMed ID: 30620668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50.
    Kuznik A; Smare C; Chen CI; Venkatachalam M; Keeping S; Atsou K; Xu Y; Wilson F; Guyot P; Chan K; Glowienka E; Konidaris G
    Value Health; 2022 Feb; 25(2):203-214. PubMed ID: 35094793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Dafni U; Tsourti Z; Vervita K; Peters S
    Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC.
    Chen P; Wang X; Zhu S; Li H; Rui M; Wang Y; Sun H; Ma A
    Front Public Health; 2022; 10():956792. PubMed ID: 36016894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study.
    Wu YL; Zhang L; Fan Y; Zhou J; Zhang L; Zhou Q; Li W; Hu C; Chen G; Zhang X; Zhou C; Dang T; Sadowski S; Kush DA; Zhou Y; Li B; Mok T
    Int J Cancer; 2021 May; 148(9):2313-2320. PubMed ID: 33231285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States.
    Huang M; Lou Y; Pellissier J; Burke T; Liu FX; Xu R; Velcheti V
    J Med Econ; 2017 Feb; 20(2):140-150. PubMed ID: 27571538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
    Wan X; Luo X; Tan C; Zeng X; Zhang Y; Peng L
    Cancer; 2019 Oct; 125(20):3526-3534. PubMed ID: 31287562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
    Liu Q; Tan C; Yi L; Wan X; Peng L; Li J; Luo X; Zeng X
    PLoS One; 2021; 16(11):e0258605. PubMed ID: 34780478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.
    Hui R; Garon EB; Goldman JW; Leighl NB; Hellmann MD; Patnaik A; Gandhi L; Eder JP; Ahn MJ; Horn L; Felip E; Carcereny E; Rangwala R; Lubiniecki GM; Zhang J; Emancipator K; Roach C; Rizvi NA
    Ann Oncol; 2017 Apr; 28(4):874-881. PubMed ID: 28168303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More.
    Zheng Z; Lin J; Zhu H; Cai H
    Front Public Health; 2022; 10():893387. PubMed ID: 35774581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
    Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
    Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.
    Teng MM; Chen SY; Yang B; Wang Y; Han RY; An MN; Dong YL; You HS
    Cancer Med; 2021 Sep; 10(18):6344-6353. PubMed ID: 34382361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of pembrolizumab + chemotherapy versus chemotherapy and pembrolizumab monotherapy in first line treatment of NSCLC in the US - updated analyses with additional trial follow-up.
    Insinga RP; Feliciano JL; Qiao N; Vandormael K; Zhang Y
    J Med Econ; 2021; 24(1):792-805. PubMed ID: 34098842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer.
    Georgieva M; da Silveira Nogueira Lima JP; Aguiar P; de Lima Lopes G; Haaland B
    Lung Cancer; 2018 Oct; 124():248-254. PubMed ID: 30268469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study.
    Zhan M; Xu T; Zheng H; He Z
    Front Public Health; 2022; 10():790225. PubMed ID: 35309225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis.
    Wu B; Lu S
    Transl Lung Cancer Res; 2020 Oct; 9(5):1770-1784. PubMed ID: 33209600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
    Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
    Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression.
    Takumida H; Horinouchi H; Masuda K; Shinno Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
    Cancer Immunol Immunother; 2022 Mar; 71(3):737-746. PubMed ID: 34389874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer.
    Huang M; Pietanza MC; Samkari A; Pellissier J; Burke T; Chandwani S; Kong F; Pickard AS
    Pharmacoeconomics; 2019 Jan; 37(1):105-116. PubMed ID: 30515719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.